[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-testicular-germ-cell-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-testicular-germ-cell-tumor":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100520769","magestic-trial-mirna-in-detecting-active-germ-cell-tumors-in-early-suspected-and-metastatic-disease-trial-100520769",false,"NCT06060873","MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial","Phase II Trial of Serum Micro RNA-371 in Detecting Active Germ Cell Tumors in Patients With Suspected Regional Disease - (MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial)","Inclusion Criteria:\n\n* Primary tumor excised by radical inguinal orchiectomy and pathology consistent with GCT (seminoma or NSGCT)\n* Clinical stage of patient is either:\n\n  * Stage I pure seminoma OR stage I pure seminoma with isolated retroperitoneal relapse or Stage IIA\u002FB pure seminoma\n  * Stage I NSGCT OR stage I NSGCT with isolated retroperitoneal relapse or Stage IIA\u002FB NSGCT\n* For subjects with retroperitoneal lymphadenopathy: no lymph node \\>3 cm in greatest dimension with no more than 2 nodes enlarged\n* Axial abdominal\u002Fpelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 3 months of enrollment if stage I patient\n* Axial abdominal\u002Fpelvic imaging (CT or MRI) and chest imaging (x-ray, CT or MRI) within 8 weeks of enrollment if stage II patient\n* miRNA-371 can be drawn and sent for analysis at time of consent\n* Enrollment within 1 year after orchiectomy for stage I patients\n* Enrollment at any timepoint after orchiectomy for stage II patients\n* Retroperitoneal lymphadenopathy must be within an RPLND template\n* Biopsy of lymph node is not required, though if biopsy of the retroperitoneal node(s) was obtained, pathology must be consistent with GCT\n* Serum Alpha Feto Protein (AFP) \\\u003C50 ng\u002Fml, β-Human Chorionic Gonadotropin (β-HCG) 25 mIU\u002Fml within 42 days (6 weeks) of enrollment\n* Age ≥ 18 years\n* Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Second primary malignancy\n* Patients receiving any other investigational agent (s)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","MALE","18 Years",{"count":19,"type":20},418,"ESTIMATED","OBSERVATIONAL","This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.",[24],"Malignant Testicular Germ Cell Tumor","RECRUITING","2026-08-19",{"date":28,"type":29},"2026-08-20","ACTUAL",{"date":31,"type":29},"2023-06-08",{"date":33,"type":20},"2028-12-08",{"name":35,"class":36},"University of Southern California","OTHER",7]